Randomized phase II clinical trial of mycophenolate mofetil in mild interstitial lung disease associated with systemic scleroderma



CHUM rheumatologist Dr. Sabrina Hoa's research team is looking for participants with scleroderma and mild interstitial lung disease for a clinical trial. This pilot study will evaluate the efficacy of mycophenolate mofetil (an immunosuppressive drug) initiated early in the mild phase of lung disease, compared with placebo.

Study participation criteria

> Female or male, 18 years of age or older

> Have systemic scleroderma

> Have been diagnosed with interstitial lung disease (or pulmonary fibrosis) for 7 years or less, with a mild stage on chest CT and a forced vital capacity of at least 80%.

> Not have progressive pulmonary fibrosis requiring immunosuppressive therapy

> Not currently being treated with mycophenolate, azathioprine, tacrolimus, tocilizumab, nintedanib, pirfenidone, a Jak inhibitor, another biologic agent, or prednisone at more than 10 mg daily; or have received cyclophosphamide within the last year; or have received rituximab within the last 6 months.

> No contraindication to mycophenolate

Involvement

> 1 eligibility visit lasting approximately 3 to 4 hours

> 12 visits during the treatment period, lasting between 30 minutes and 3 hours, spanning over 2 years

> 1 follow-up telephone visit lasting around 15 minutes

> The drug mycophenolate mofetil will be provided free of charge by the sponsor.

Interested in taking part in the project? Contact

Dr. Sabrina Hoa
sabrina.anh-tu.hoa.med@ssss.gouv.qc.ca
or uit.eligibilite.chum@ssss.gouv.qc.ca.

CRCHUM
RESEARCH CENTRE